Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Tekcapital Plc LSE:TEK London Ordinary Share GB00BKXGY798 ORD �0.004
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 11.00 4,848 08:00:08
Bid Price Offer Price High Price Low Price Open Price
10.50 11.50 11.00 11.00 11.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Technology Hardware & Equipment 5.36 3.57 8.08 1.4 10
Last Trade Time Trade Type Trade Size Trade Price Currency
08:16:54 O 4,848 10.521 GBX

Tekcapital (TEK) Latest News

More Tekcapital News
Tekcapital Investors    Tekcapital Takeover Rumours

Tekcapital (TEK) Discussions and Chat

Tekcapital (TEK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:16:5510.524,848510.06O
View all Tekcapital trades in real-time

Tekcapital (TEK) Top Chat Posts

DateSubject
30/11/2020
08:20
Tekcapital Daily Update: Tekcapital Plc is listed in the Technology Hardware & Equipment sector of the London Stock Exchange with ticker TEK. The last closing price for Tekcapital was 11p.
Tekcapital Plc has a 4 week average price of 8.25p and a 12 week average price of 8.25p.
The 1 year high share price is 23p while the 1 year low share price is currently 3.75p.
There are currently 92,828,042 shares in issue and the average daily traded volume is 334,801 shares. The market capitalisation of Tekcapital Plc is £10,211,084.62.
17/11/2020
13:49
mr.oz: Am encouraged that a relatively small amount has been raised to further TEK on several fronts toward commercial success or even spin-off/asset sale NDAs sound interesting FDA quite close Saltme and Lucyd revenue makers soon. Patience could be rewarded handsomely hTTps://www.voxmarkets.co.uk/articles/tekcapital-0-38m-at-8p-to-advance-guident-and-salarius--33cb783/
28/10/2020
07:56
scoble2: Lucyd Receives Notice of Allowance for IOT Utility Patent & 13 Design Patents Tekcapital Plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, is pleased to announce portfolio company Lucyd Ltd, ("Lucyd") the developer of E-glasses and operator of an eShop for advanced eyewear, announces new updates to its intellectual property position.
17/10/2020
21:07
camo1997: Been watching this for a while, and like the main business model. Looking over the fundamentals looks promising, BV of near 30p and future value in 2yrs at this current rate of 54p ish. From their recent report, debt ratio very very low and other bits in the balance sheet look good. Looks like it has been diluted though over the years, however can't quite see why the share price not higher. Also can't see its too correlated to the main market, so may be good during these times. Management looks good as well, most of which went to Oxford (not sure if that's a good thing or not lol). Worth a punt, any thoughts? Will get to know you guys lol, may be here a bit more. Few main bits Date 2020 Debt Ratio 0.009 Current Ratio 8.69 Cash ratio 4.33 Date 2020 PE 4.04 EPS 0.03 EPS Growth -59% Mean Return 12.62% Volatility 37.29% Skew 0.772 Kurtosis -0.240 Beta (FTSE 100) 0.385 Correlation (FTSE 100) 0.059 R^2 (FTSE 100) 0.004 Date 2020 Book Value Per Share 0.297 Share Price 0.105 Price to Book 0.353 Book Value Growth 16%
16/9/2020
14:15
under the radar: OT ... Heads up (BOR) Borders and Southern :- 1)465m barrels of condensate (light sweet crude) 2)Own 100% of all acreage 3)Darwin (discovery) costs are under $35 a barrel 4)474m shares in issue 5)£3m mkt cap = nothing at all priced in and priced to fail 6)Bod own over 10% of shares 7)Rkh sea lion will get sanctioned next year which will do wonders for BOR 8)Bottomed - no sellers left as all flushed out 9)Bullish divergence on chart with bullish white candles being formed and it’s totally oversold on stochastic rsi 10)Enough money to last until April 2023 11)Update due in next 2 weeks The Market was over pessimistic and now a correction is due (it’s JUST starting now) Share price 0.7525p - it won’t be under 1p for long imho Put it on your watch list at the very least and see for yourself what happens I wish you luck whatever you decide! ATB
16/9/2020
09:05
29palms: A point of order to the Self-Aggrandiser superg1 Oh I say.....among the top LSE Leaders today we have TEK(Tekcapital) showing a 30% gain. This is a stock you tried to attack with your aggrandised drivel just as you are trying on another BB thread with VDTK Welcome to the "Karma Cafe" As a footnote we have no menu available "You just get what you deserve"
07/9/2020
08:07
scoble2: patience is the virtue. It has a market capitalisation of £9m, with approximately 88m shares in issue. Over the last year, TekCapital share price has been traded in a range of 17.3, hitting a high of 21, and a low of 3.7.
20/3/2020
08:38
philjeans: Belluscura 19% interest. That company has some game changing kit due to launch this year, so what value for that company. Currently as it stands £1 mill profit for TEK on a 15 PE is 18.75p on the share price That means 5.5p equates to a 15 PE profit rate of £300k. Just COPD costs the NHS about £10 bill per year, 30,000 deaths each year. The UK estimates 3 mill have it with about 1/3rd currently diagnosed. 1 in 8 hospital admissions in the UK is for COPD, yet it seems few know much about it. 2015 data and the problem is growing. Worldwide estimates 250 mill sufferers 3.2 mill deaths per year. Again 2015 others suggest over 300 million. So with Belluscura producing what looks like a transformational easily portable oxygen unit, which requires no oxygen tank, then it seems a big leap in convenience and costs for those that suffer with it. So to me 19% of Belluscura alone with FDA approval weeks away and launch this year, is put potentially worth far more than the share price.
17/3/2020
08:39
superg1: iam You can't call a £4 mill MC cap over-priced imo under the circs of where they are now. Certain parts are jun k imo but the salt is gaining traction, products launched 97.5% owned. Belluscura 19% interest. That company has some game changing kit due to launch this year, so what value for that company. Currently as it stands £1 mill profit for TEK on a 15 PE is 18.75p on the share price That means 5.5p equates to a 15 PE profit rate of £300k. Just COPD costs the NHS about £10 bill per year, 30,000 deaths each year. The UK estimates 3 mill have it with about 1/3rd currently diagnosed. 1 in 8 hospital admissions in the UK is for COPD, yet it seems few know much about it. 2015 data and the problem is growing. Worldwide estimates 250 mill sufferers 3.2 mill deaths per year. Again 2015 others suggest over 300 million. So with Belluscura producing what looks like a transformational easily portable oxygen unit, which requires no oxygen tank, then it seems a big leap in convenience and costs for those that suffer with it. So to me 19% of Belluscura alone with FDA approval weeks away and launch this year, is put potentially worth far more than the share price. Just my view. Cold and flu viruses for such sufferers severely compound their illness.
26/6/2019
06:06
someuwin: 26 June 2019 Tekcapital Plc ("Tekcapital", the "Company" or "the Group") Portfolio Company Update: Belluscura plc On track to likely receive FDA clearance later this year Tekcapital Plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, is pleased to announce that its portfolio company Belluscura plc has received commitments for GBP725,000 of additional funding at 15p/share and is on track to receive FDA clearance later this year followed by commercial launch in H1 2020. The Product Belluscura has developed a patented portable oxygen concentrator called the X-PLOR, that can deliver 96% pure oxygen to patients 24/7. According to the Company(1) , the X-PLOR is designed to replace metal oxygen tanks and heavier devices. Weighing only 1.4kg, X-PLOR is 33% lighter and research suggests can provide 37% more oxygen per kg than leading competitors. X-PLOR is portable, increasing the mobility of people suffering from COPD and price efficient, costing less than tanks over the duration of the disease, and is upgradeable with user replaceable filters, so as the disease progresses, there is no need to buy another expensive higher capacity device, rather just change the filter as the prescription changes. Belluscura has exclusively licensed, acquired or filed 13 patents and applications in the field of concentrated oxygen generation and has a robust pipeline with additional oxygen enrichment products planned for release in 2020. Market Information Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease. Over 250 million people worldwide suffer from COPD(2) . COPD is not curable, but patients with COPD are prescribed supplemental oxygen to help relieve shortness of breath and reduce the risk of death. According to the British Lung Foundation, in the U.K. an estimated 1.2 million people are living with diagnosed COPD.(3) Globally, the medical portable O(2) concentrator market is expected to grow from $1.4bn in 2018 to $2.4bn by 2024, with a CAGR of 9%.(4) Dr Clifford Gross, Chairman at Tekcapital commented, "We are delighted to see that Belluscura has strengthened its balance sheet and is on track to likely receive FDA clearance later this year. The fundraise was conducted at 15p per share, a 50% uplift over the valuation Tekcapital listed for Belluscura in its 2018 Annual Accounts. The Directors believe that Belluscura's new device will help to improve the quality of life and reduce treatment cost for individuals suffering from COPD." Tekcapital owns approximately 21.7% (9.3m shares) of Belluscura plc. About Belluscura plc Belluscura plc is an English company that is focused on improving healthcare and people's lives by developing new and innovative treatment platforms. They license and develop proprietary technologies that can be applied across a range of treatment possibilities. To learn more please visit www.belluscura.com. About Tekcapital plc Tekcapital creates value from investing in new, university-developed intellectual properties and provides a range of IP investment services to make it easy for organisations to commercialise university-developed technology. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com
24/6/2019
06:05
someuwin: 24 June 2019 Tekcapital Plc ("Tekcapital", the "Company" or "the Group") Portfolio Company Update: Salarius Secures New Order for MicroSalt(R) Tekcapital Plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, is very pleased to announce that its portfolio company Salarius ltd. has secured & delivered a new order for MicroSalt(R) from a Mexican seafood company for use in their dried shrimp snacks. MicroSalt(R) is a proprietary salt made with micron-size salt particles that dissolve in the mouth significantly faster than regular salt, delivering an increased sensation of saltiness with much less salt, and as a result approximately 50% less sodium. "Consumer demand for better for you snack options continues to drive marketplace adoption of low sodium snacks. Snacks made with MicroSalt(R) will help consumers reduce sodium consumption while providing the great salty taste they enjoy. MicroSalt(R) is non-GMO and all natural. Salarius is in discussions with numerous snack food companies who are evaluating MicroSalt(R) for possible inclusion in their products, and we will update the market in due course," said Victor Hugo Manzanilla, CEO of Salarius. High blood pressure is a key risk factor for developing heart disease. Consistent with this, a new report from the National Academies of Sciences, Engineering, and Medicine has recommended significantly reduced sodium consumption guidelines(1) . Salarius' MicroSalt(R) can empower food companies and consumers to meet these new guidelines. Market Information The highly competitive global savory snacks market is expected to reach US$108 billion by 2021(2) . The low sodium ingredient market is estimated to reach US$1.76 billion by 2025 with a CAGR 11.7%(3) . "Both markets could immediately benefit from the availability of MicroSalt(R). Additionally, the smaller crystals provide better adhesion to the food surface. This reduces the amount of salt that falls off products during transport and display, thus reducing waste and helping to ensure a consistent flavor profile," says Manzanilla. Dr Clifford Gross, Executive Chairman at Tekcapital, commented: "We are delighted with Salarius' continued progress. MicroSalt(R) has the potential to help companies and consumers worldwide enjoy full-flavour snacks with reduced sodium." Tekcapital owns 97.5% of the share capital of Salarius ltd. About Salarius ltd Salarius, is the developer and manufacturer of a proprietary low sodium salt called MicroSalt(R). Salarius is passionate about improving lives with healthier food and is taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavor, because it is salt. The technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. MicroSalt(R) is a registered trademark of Salarius Ltd. To learn more please visit https://Salarius.co. About Tekcapital plc Tekcapital creates value from investing in new, university-developed intellectual properties and provides a range of IP investment services to make it easy for organisations to commercialise university-developed technology. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com
Tekcapital share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
TEK
Tekcapital
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201130 09:17:03